Literature DB >> 18583368

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

J Koivunen1, A Verkkoniemi, S Aalto, A Paetau, J-P Ahonen, M Viitanen, K Någren, J Rokka, M Haaparanta, H Kalimo, J O Rinne.   

Abstract

Variant Alzheimer's disease (VarAD) with spastic paraparesis and presenile dementia is associated with certain mutations of the presenilin 1 (PS-1) gene, particularly those leading to deletion of exon 9 (PS-1Delta E9). VarAD is neuropathologically characterized by the presence of unusually large, Abeta42 positive, non-cored 'cotton wool' plaques (CWPs), also devoid of dystrophic neurites. The aim of the present study was to find out whether [(11)C]PIB would show increased uptake and serve as an in vivo biomarker of amyloid accumulation in VarAD. A further aim was to assess the correspondence of the [(11)C]PIB binding to the amount and type of Abeta deposits in another group of deceased VarAD patients' brains. We studied four patients with VarAD and eight healthy controls with PET using [(11)C]PIB as tracer. Parametric images were computed by calculating the region-to-cerebellum and region-to-pons ratio in each voxel over 60-90 min. Group differences in [(11)C]PIB uptake were analysed with automated region-of-interest (ROI) analysis. [(11)C]PIB uptake was compared to the immunohistochemically demonstrated deposition of Abeta in the brains of another group of four deceased VarAD patients. Patients with VarAD had significantly higher [(11)C] PIB uptake than the control group in the striatum (caudate nucleus and putamen), anterior and posterior cingulate gyrus, occipital cortex and thalamus. In the caudate and putamen [(11)C]PIB uptake, expressed as region-to-cerebellum ratio, was on the average 43% greater than the mean of the control group. The increases in the anterior (28%) and posterior (27%) cingulate gyrus, occipital cortex (21%) and thalamus (14%) were smaller. All VarAD patients showed this similar topographical pattern of increased [(11)C]PIB uptake. The results were essentially similar when the uptake was expressed as region-to-pons ratios. [(11)C]PIB imaging shows increased uptake in patients with VarAD especially in the striatum, and it can be used to detect amyloid accumulation in vivo in these patients. The pattern of increased [(11)C]PIB uptake is different from that described in sporadic Alzheimer's disease and resembles that seen in Alzheimer's disease patients with certain presenilin-1 mutations or amyloid precursor protein gene duplication showing predominantly striatal increase in [(11)C]PIB uptake.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583368     DOI: 10.1093/brain/awn107

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  50 in total

1.  Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task.

Authors:  John M Ringman; Luis D Medina; Meredith Braskie; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel A Macias-Islas; Jeffrey L Cummings; Susan Bookheimer
Journal:  Cereb Cortex       Date:  2010-08-20       Impact factor: 5.357

Review 2.  Clinical applications of PET amyloid imaging: an update.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

3.  Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

Authors:  Linda D Nelson; Prabha Siddarth; Vladimir Kepe; Kevin E Scheibel; S C Huang; Jorge R Barrio; Gary W Small
Journal:  Arch Neurol       Date:  2011-06

Review 4.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Authors:  Lisa Mosconi; Valentina Berti; Lidia Glodzik; Alberto Pupi; Susan De Santi; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

6.  Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging.

Authors:  Thomas G Beach; Lucia I Sue; Douglas G Walker; Marwan N Sabbagh; Geidy Serrano; Brittany N Dugger; Monica Mariner; Kim Yantos; Jonette Henry-Watson; Glenn Chiarolanza; Jose A Hidalgo; Leslie Souders
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 7.  Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Authors:  G D Rabinovici; W J Jagust
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

8.  Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia.

Authors:  Nicholas J Janocko; Kevin A Brodersen; Alexandra I Soto-Ortolaza; Owen A Ross; Amanda M Liesinger; Ranjan Duara; Neill R Graff-Radford; Dennis W Dickson; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2012-09-12       Impact factor: 17.088

Review 9.  Molecular and cellular pathophysiology of preclinical Alzheimer's disease.

Authors:  Elliott J Mufson; Milos D Ikonomovic; Scott E Counts; Sylvia E Perez; Michael Malek-Ahmadi; Stephen W Scheff; Stephen D Ginsberg
Journal:  Behav Brain Res       Date:  2016-05-13       Impact factor: 3.332

10.  Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Dietmar R Thal; Thomas Arzberger; Nenad Bogdanovic; Safa Al-Sarraj; Istvan Bodi; Susan Boluda; Orso Bugiani; Charles Duyckaerts; Ellen Gelpi; Stephen Gentleman; Giorgio Giaccone; Manuel Graeber; Tibor Hortobagyi; Romana Höftberger; Paul Ince; James W Ironside; Nikolaos Kavantzas; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Camelia Monoranu; Tatjana Nilsson; Piero Parchi; Efstratios Patsouris; Maria Pikkarainen; Tamas Revesz; Annemieke Rozemuller; Danielle Seilhean; Walter Schulz-Schaeffer; Nathalie Streichenberger; Stephen B Wharton; Hans Kretzschmar
Journal:  Acta Neuropathol       Date:  2009-02-01       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.